Why the study?
Do phosphodiesterase inhibitors affect the antilipolytic effect of insulin in healthy subjects?
Population
Healthy subjects
Comparison
Local perfusion with a selective PDE IV… vs Local perfusion with Ringer's solution alone
Design
Other
Follow-up
2 hours
Authors
Loading...
PDE III inhibition may blunt insulin antilipolysis in vivo; leaves open its therapeutic targeting in metabolic disease.
Do phosphodiesterase inhibitors affect the antilipolytic effect of insulin in healthy subjects?
Phosphodiesterase III is the dominant isoenzyme mediating the antilipolytic effect of insulin in vivo.
Toft et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: